San Francisco, CA 8 September 2025 – Caresyntax, a global leader in surgical intelligence and real-world evidence (RWE) solutions, and Paragonix Technologies, a pioneer in organ transplant innovation, today announced a strategic partnership to advance the collection of real-world data (RWD) for the GUARDIAN family of registries—a series of multi-national, industry-leading data registries to improve transplant outcomes. This multi-phase collaboration will significantly enhance the registries’ capabilities, expand data collection, and strengthen their clinical utility.
To the partnership, Caresyntax will contribute technology and services from its Clinical Data-as-a-service (CDaaS) platform, including the Adaptive Registry Module, which enables wraparound data collection for any existing post-market registry or data collection effort. Paragonix will contribute its expertise in state–of-the–art controlled hypothermic preservation, along with collaboration with key champions from select clinical sites. The agreement will initially focus on heart and lung transplantation, before broadening scope to include all solid organs to shape a new value-based registry for organ transplantation.
“Organ transplants are among the highest-complexity procedures in all of surgery, and transplant teams need access to the highest-quality data. Together with Paragonix, we’re using real-world evidence to define what a next-generation transplant registry should look like—one that reflects how care is delivered and enables analysis to measure and improve outcomes in each clinical environment.”
– Dr. Bruce Ramshaw, CMIO Caresyntax
“Since 2019, we have been a leader in transplant preservation research through our GUARDIAN ClinicalRegistries. This real world evidence partnership aims to advance our real world data initiatives, foster collaboration, and ultimately drive advancements across the field of organ transplantation.”
– Michael Tajima, Chief Strategy Officer Paragonix
About Caresyntax
Caresyntax powers surgical performance and outcomes through AI-enabled analytics, real-world evidence, and workflow integration tools. Its regulatory-grade platform supports health systems, payers, and life sciences companies globally.
Caresyntax is dedicated to making surgery smarter and safer. Our mission is to merge AI-powered software, devices, and clinical services into a surgical intelligence platform to enhance surgical outcomes. The platform generates insights across the entire continuum of care—before surgery with workflow optimization, during surgery with real-time support tools, and after procedures with clinical safety modules. It also provides data analytics for medical device companies, insurers, and other stakeholders to drive innovation and improve healthcare delivery.
Headquartered in San Francisco, with an international presence in Berlin, Caresyntax software is used in over 4,000 operating rooms globally and supports more than three million procedures annually. To learn more, visit www.caresyntax.com.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.
A Getinge company, Paragonix Technologies provides Advanced Organ Preservation (“AOP”) devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.
